Patients with hard-to-treat autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC) are defined a posteriori as those who do not show a sufficient response or are intolerant to pharmacological treatments, thus not achieving biochemical surrogate endpoints that are associated with long-term liver-related-event-free survival. The absence of a recently harmonized definition of ‘complete biochemical response within 6 months (CBR≤6M)’, which is defined as the normalization of serum transaminase and IgG levels below the upper limit of normal at ≤6 months after treatment initiation, is regarded as hard-to-treat AIH. The implementation of CBR≤6M, in turn, has been facilitating clinical trials, e.g., between azathioprine and mycophenolate mofetil, to reconsider appropriate first-line steroid sparing agents, leading to a reduction in the number of hard-to-treat AIH cases. Regarding PBC, one of the disseminated definitions of hard-to-treat patients is the absence of POISE criteria, which are evaluated at 12 months with serum alkaline phosphatase and bilirubin levels, after the introduction of ursodeoxycholic acid. Hard-to-treat PBC not meeting the POISE criteria has very recently been the target population for the U.S. FDA-approved second-line drugs, elafibranor and seladelpar. In future pharmacological treatment of AIH and PBC, the primary objective for AIH is likely to focus on lowering the number of hard-to-treat patients with personalized steroid sparing treatment regimens. A challenging goal in PBC treatment is the further optimization of treatment surrogate endpoints, even to the stricter alkaline phosphatase normalization, with which an indication of second- or later-line drugs might be expanded, but could ultimately lengthen patients’ long-term survival.
Citations
Citations to this article as recorded by
Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey Yuki Kugiyama, Masanori Abe, Tadashi Namisaki, Hitoshi Yoshiji, Kazumichi Abe, Hiromasa Ohira, Ryosaku Shirahashi, Keiji Yokoyama, Atsushi Fukunaga, Kazuhito Kawata, Masahiro Umemura, Akira Honda, Tadashi Ikegami, Shiho Miyase, Toshiaki Nakano, Atsumasa K Hepatology Research.2026; 56(1): 50. CrossRef
Autoimmune Hepatitis: Histopathological Diversity and Its Clinical Implications Mina Komuta, Kenichi Harada Hepatology Research.2026; 56(2): 139. CrossRef
Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalentl Mehrangiz Dezhbord, Kyun-Hwan Kim Clinical and Molecular Hepatology.2026; 32(1): 385. CrossRef
PBC-AIH Overlap Syndrome: Diagnostic Challenges, Clinical Recognition of the
“Grey Zone” and Treatment Updates 红静 王 Advances in Clinical Medicine.2026; 16(04): 2281. CrossRef
Autoimmune Hepatitis: Emerging Frontiers in Research and Clinical Management Armando Curto, Irene Scami, Giulia Gliottone, Rocco G. Iamello, Erica N. Lynch, Andrea Galli Gastrointestinal Disorders.2026; 8(2): 20. CrossRef
Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics Zefeng Zhang Frontiers in Immunology.2026;[Epub] CrossRef
Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review Tatsuo Kanda, Reina Sasaki-Tanaka, Naruhiro Kimura, Hiroyuki Abe, Tomoaki Yoshida, Kazunao Hayashi, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Atsunori Tsuchiya, Kenya Kamimura, Shuji Terai International Journal of Molecular Sciences.2025; 26(5): 1883. CrossRef
The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine Xinyi Men, Yansheng Liu, Han Zhao, Bingrui Xie, Changcun Guo, Patrick S. C. Leung, Suraj Timilsina, M. Eric Gershwin, Yulong Shang, Ying Han Clinical Reviews in Allergy & Immunology.2025;[Epub] CrossRef
Autoimmune Hepatitis: Histopathological Spectrum and Diagnostic Implications Mina Komuta, Kenichi Harada Kanzo.2025; 66(11): 473. CrossRef
First
Prev
